Piracetam (Epilepsy = All indications) - Medication and Pregnancy KB

Piracetam (Epilepsy = All indications)

Exposed non-exposed, cohort studies

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
Morrow (Piracetam) (Controls exposed to Lamotrigine, sick) 2006	UK and Ireland 1996 - 2005 prospective cohort	The UK Epilepsy and Pregnancy Register	Infants of women with epilepsy exposed to piracetam in monotherapy during the first trimester. (This is a subgroup of exposure among the whole exposed group considered in the study).	exposed to other treatment, sick Infants of women with epilepsy exposed to lamotrigine in monotherapy during the first trimester.	1st trimester	1 / 647	Exposure period is completed thanks to Campbell 2014 which is also a UKEPR based study.
	UK and Ireland 1996 - 2005 prospective cohort	The UK Epilepsy and Pregnancy Register	Information was collected at registration and changes of antiepileptic drugs during pregnancy were detected during the follow-up duration by sending a standardised questionnaire to the patient's general practitioner. Other health care practitioners were contacted if identified.		1st trimester	1 / 647
Morrow (Piracetam) (Controls unexposed, sick) 2006	UK and Ireland 1996 - 2005 prospective cohort	The UK Epilepsy and Pregnancy Register	Infants of women with epilepsy exposed to piracetam in monotherapy during the first trimester. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, sick Infants of women with epilepsy and who didn't take any antiepileptic drugs during pregnancy.	1st trimester	1 / 227	Exposure period is completed thanks to Campbell 2014 which is also a UKEPR based study.
Morrow (Piracetam) (Controls unexposed, sick) 2006	UK and Ireland 1996 - 2005 prospective cohort	The UK Epilepsy and Pregnancy Register	Information was collected at registration and changes of antiepileptic drugs during pregnancy were detected during the follow-up duration by sending a standardised questionnaire to the patient's general practitioner. Other health care practitioners were contacted if identified.		1st trimester	1 / 227

Case-control studies

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;

Empty. There are no case-control studies available for this drug.

master protocol